What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lipodystrophy, HIV Infections, Chronic Obstructive Pulmonary Disease (COPD)
- Main trialPhase 3
- “Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation”In the company’s words, NCT00608023 on ClinicalTrials.gov
- Other names
- Egrifta
Other drugs for HIV Infections
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- IslatravirMerck & Co. · Phase 2/3
- UlonivirineMerck & Co. · Phase 2/3
- DOVATOViiV Healthcare · Phase 3
- ISL/ULOMerck & Co. · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | Oct 2008 | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | |
| Phase 2Terminated | Dec 2011 | Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026